6:19 PM
 | 
Mar 27, 2007
 |  BC Extra  |  Top Story

FDA posts Provenge documents

Data submitted by Dendreon (DNDN) on Provenge sipuleucel-T "tend to support a finding of clinically meaningful increased survival, but doubts remain about the persuasiveness of the efficacy data," FDA concluded in a briefing document released ahead of Thursday's advisory committee meeting. DNDN is seeking approval of the autologous dendritic cell therapy to treat asymptomatic patients with metastatic, androgen-independent...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >